Bovine Herpesvirus 1 VP22 Enhances the Efficacy of a DNA Vaccine in Cattle
Open Access
- 1 February 2005
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (3) , 1948-1953
- https://doi.org/10.1128/jvi.79.3.1948-1953.2005
Abstract
For this study, the intercellular trafficking ability of bovine herpesvirus 1 (BHV-1) VP22 was applied to improve the efficacy of a DNA vaccine in calves. A plasmid encoding a truncated version of glycoprotein D (tgD) fused to VP22 was constructed. The plasmid encoding tgD-VP22 elicited significantly enhanced and more balanced immune responses than those induced by a plasmid encoding tgD. Furthermore, protection against a BHV-1 challenge was obtained in calves immunized with the plasmid encoding tgD-VP22, as shown by significant reductions in viral excretion. However, less significant protection was observed for animals vaccinated with the tgD-expressing plasmid, correlating with the lower level of immunity observed prechallenge. This is the first report of the use of VP22 as a transport molecule in the context of a DNA vaccine for a large animal species.Keywords
This publication has 35 references indexed in Scilit:
- Vaccination with a DNA Vaccine Encoding Herpes Simplex Virus Type 1 VP22 Linked to Antigen Generates Long-Term Antigen-Specific CD8-Positive Memory T Cells and Protective ImmunityHuman Gene Therapy, 2004
- Induction of immune responses by DNA vaccines in large animalsVaccine, 2003
- The Immunogenicity and Protective Efficacy of Bovine Herpesvirus 1 Glycoprotein D plus Emulsigen Are Increased by Formulation with CpG OligodeoxynucleotidesJournal of Virology, 2002
- Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an AntigenJournal of Virology, 2002
- Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22–Antigen FusionHuman Gene Therapy, 2002
- Intratumoral Spread and Increased Efficacy of a p53-VP22 Fusion Protein Expressed by a Recombinant AdenovirusJournal of Virology, 2001
- A Genetic Immunization Adjuvant System Based on BVP22–Antigen FusionHuman Gene Therapy, 2001
- Intercellular spread of GFP-VP22The Journal of Gene Medicine, 1999
- Intercellular trafficking of VP22-GFP fusion proteins is not observed in cultured mammalian cellsGene Therapy, 1998
- INDUCTION OF TH1 AND TH2 CD4+T CELL RESPONSES:The Alternative ApproachesAnnual Review of Immunology, 1997